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Sensorineural hearing loss is the most common long-term deficit after pneumococcal
meningitis (PM), occurring in up to 30% of surviving patients. The infection and the
following overshooting inflammatory host response damage the vulnerable sensory cells
of the inner ear, resulting in loss of hair cells and spiral ganglion neurons, ultimately
leading to elevated hearing thresholds. Here, we tested the oto-protective properties
of the small heat shock protein alpha B-crystallin (HspB5) with previously reported
anti-inflammatory, anti-apoptotic and neuroprotective functions, in an experimental
model of PM-induced hearing loss. We analyzed the effect of local and systemic delivery
of HspB5 in an infant rat model of PM, as well as ex vivo, using whole mount cultures.
Cytokine secretion profile, hearing thresholds and inner ear damage were assessed at
predefined stages of the disease up to 1 month after infection. PM was accompanied
by elevated pro-inflammatory cytokine concentrations in the cerebrospinal fluid (CSF),
leukocyte and neutrophil infiltration in the perilymphatic spaces of the cochlea with
neutrophils extracellular trap formation during the acute phase of the disease. Elevated
hearing thresholds were measured after recovery from meningitis. Intracisternal but not
intraperitoneal administration of HspB5 significantly reduced the levels of TNF-α, IL-6
IFN-γ and IL-10 in the acute phase of the disease. This resulted in a greater outer hair
cell survival, as well as improved hearing thresholds at later stages. These results suggest
that high local concentrations of HspB5 are needed to prevent inner ear damage in acute
PM. HspB5 represents a promising therapeutic option to improve the auditory outcome
and counteract hearing loss after PM.
Keywords: sensorineural hearing loss, S.pneumoniae, HspB5, inflammation, oto-protection, hair cells, neutrophil
infiltration
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INTRODUCTION
Worldwide around 460 million people suffer from disabling
hearing loss (world health organization fact sheet 2019). This
is caused by inherited genetic defects or acquired damage by
ototoxic drugs, exposure to excessive noise, aging or certain
infectious diseases such as meningitis. Streptococcus pneumoniae
is the most common and simultaneously the most severe
pathogen causing bacterial meningitis. Pneumococcal meningitis
(PM) is associated with high mortality and risk for neurological
sequelae, with sensorineural hearing loss representing the most
frequent long term deficit (1) occurring in up to 30% of surviving
patients (2).
Bacterial meningitis evokes a robust inflammatory response
marked by recruitment of leukocytes, mostly polymorphonuclear
neutrophils, to the cerebrospinal fluid (CSF) spaces, including the
inner ear. For many years the cochlea was thought to be immune-
privileged, but more recent studies have shown that resident
macrophages are present in the lateral wall, in the spiral limbus
and in the basal side of basilar membrane and are activated after
insult (3–7).
Upon infection, pro-inflammatory cytokines such as TNFα,
IL-1β, IL-6, IL-8 are secreted in the CSF (8, 9) and pneumococci
and leukocytes infiltrate the perilymphatic space of the
inner ear via the cochlear aqueduct (1, 6, 10). These
processes, together with the release of the bacterial exotoxin
pneumolysin, cause an accentuated inflammation of the inner
ear, especially in the basal portion of the cochlea (11,
12). This results in histopathological changes of the sensory
epithelium and associated structures, which are crucial for
the hearing process. Spiral ganglion neuron loss and outer
hair cell loss strongly correlate to the level of pneumococcal
infection, with the most severe damage occurring in the
basal part of the cochlea (8). Inner hair cells are not
significantly lost but the number of presynaptic ribbons was
shown to be decreased (8). Increased hearing thresholds are
already observed during the acute phase of experimental
pneumococcal meningitis and in most cases persist until later
stages (8, 12–14).
Current treatment options for sensorineural hearing loss
consist of hearing aids and cochlear implants, both relying
for their effectiveness on remaining intact hair cells and/or
spiral ganglion neurons (15). Novel therapeutics are highly
needed to protect these cells in the first place or to induce a
regenerative response.
Heat shock proteins have already been proposed as
therapeutic targets in various diseases (16). Activation of
heat shock proteins is the most ubiquitous and highly conserved
stress response in biology (17, 18).
Specific to the inner ear, May et al. observed a protective effect
of Hsp70 against aminoglycoside-induced hair cell death in vitro
and in vivo (19). Additionally, expression of Hsp70 and induction
of Hsp32 offered protection against cisplatin-induced hair cell
death in utricle cultures (20).
Over the last decade, evidence has accumulated for the
broad neuroprotective and anti-inflammatory activity of HspB5,
also known as alpha B-crystallin or CRYAB (21, 22). Several
studies demonstrated HspB5-mediated cell protection under
various stress conditions (23) such as experimental autoimmune
encephalomyelitis (24), stroke (25) and Alexander disease (26).
HspB5 is a member of the small heat shock family that is
constitutively expressed in many tissues and especially abundant
in eye, lens, heart, muscle and oligodendrocytes of the CNS
(21, 23). In pathological conditions such as multiple sclerosis and
brain ischemia it is also expressed in other glial cells (21, 27).
HspB5 is stress-inducible (22) and has anti-apoptotic (28, 29),
anti-inflammatory (21) and neuroprotective (30) functions.
Different mechanisms of action have been reported for HspB5
in the literature. The anti-inflammatory effect of HspB5 has been
shown to be associated with activation of an immune-regulatory
macrophage response via Toll-like receptors (TLR1/2) and the
co-receptor CD14 (31, 32). Its chaperone activity, by binding
to misfolded proteins also contributes to its anti-inflammatory
activity (24, 26). Its anti-apoptotic effects have been instead
attributed to direct interaction with pro-apoptotic molecules,
such as Caspase-3, or by interfering with cytochrome C release
from the mitochondria (33).
In a murine model of stroke, Cryab−/− mice had increased
lesion size and diminished neurologic function compared with
wild-type mice. Even 12 h after experimental stroke, systemic
administration of HspB5 reduced both stroke volume and
inflammatory cytokines associated with stroke pathology (25).
Furthermore, in a model of experimental autoimmune
encephalomyelitis Cryab−/− mice showed worse scores in
the acute and in the progressive phases, with higher Th1 and
Th17 cytokine secretion and more intense CNS inflammation
compared with their wild-type counterparts. Moreover,
Cryab−/− astrocytes showed increased expression of cell death
markers, such as cleaved caspase-3 and DNA breaks, detected
by TUNEL staining, indicating an anti-apoptotic function of
HspB5. Administration of recombinant HspB5 ameliorated
experimental autoimmune encephalomyelitis (21).
A phase IIa randomized clinical trial with therapeutic
application of HspB5 in relapsing-remitting multiple sclerosis
patients, using intravenous doses of HspB5 was completed in
2015. Repeated administration of the lower doses of HspB5
resulted in a progressive decline in MS lesion activity, which was
not seen in the placebo group (22).
Considering the abundance of HspB5 expression in
peripheral tissues and its potential therapeutic value for
counteracting inflammation and supporting neuroprotection,
HspB5 is a promising candidate to test in the context of
infection/inflammation-induced sensorineural hearing loss.
The aim of this study was to characterize the acute
inflammatory phase of the disease upon infection and evaluate
whether exogenous human recombinant HspB5 could be used to
protect cochlear neurosensory cells in an infant rat model of S.
pneumoniae-induced bacterial meningitis.
METHODS AND MATERIALS
All animal experiments were approved by the experimentation
committee of the canton Bern, Switzerland (license to SSL
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BE124/16 and BE1/18) and followed the Swiss national guidelines
for the performance of animal experiments.
HspB5
For this study, GMP-grade sterile recombinant human HSPB5
(Delta Crystallon BV, Leiden, The Netherlands), was used.
Previous analysis reported 5 ng/mg (0.0005 %) E. Coli proteins,
<0.7 EU/mg endotoxins, and <75 pg/mg bacterial DNA.
Streptococcus pneumoniae Inoculum
A clinical isolate of Streptococcus pneumoniae (serotype 3) from
a patient with bacterial meningitis had been adapted to rats
through several in vivo passages and was prepared as previously
reported (8, 34). Bacteria were cultured overnight in brain-heart
infusion medium. Then the bacterial culture was diluted 1:10 in
fresh medium and grown for another 5 h until the logarithmic
phase was reached. The bacterial culture was centrifuged for
10min at 3,100 g at 4◦C. The pellet was re-suspended in 0.85
% NaCl followed by a second centrifugation and then diluted
to the desired concentration by optical density measurements
at 570 nm. Final inoculum concentration was later quantified by
plating serial dilutions of the inoculum on Columbia sheep blood
agar (CSBA) plates.
Infant Rat Model of Pneumococcal
Meningitis With Therapeutic Intervention
by HspB5
A well-established infant rat model of experimental
pneumococcal meningitis was used as previously described
(14, 35). A schematic is given in Figure 3A. Eleven-day old
Wistar rats obtained from Charles River Laboratories (Sulzfeld,
Germany) were infected by a single intracisternal injection of S.
pneumoniae (10 µl of 8.20 ± 1.8 × 105 cfu/ml). Control animals
received same volume of saline (0.85 % NaCl). During the acute
phase of meningitis, animals were weighted and clinically scored
at 0, 18, 24, and 42 h post infection (hpi), as previously described
(35). Disease symptoms were recorded and scored as follows: 1=
minimal or no spontaneous motor activity, coma; 2 = unable to
turn upright within 30 s; 3 = turns upright within 30 s; 4 = signs
of disease in terms of weight loss and/or appearance of fur, turns
upright within 5 s; 5 = normal behavior, healthy. Spontaneous
mortality was documented. Animals were sacrificed if scored 2
or lower.
Punctures of the cisterna magna were performed using a 30-
gauge needle to collect CSF samples at 18 hpi, 24 hpi and 42 hpi to
follow the inflammatory cytokine secretion pattern. A volume of
about 15µl was collected per animal per time point. CSF samples
collected at 18 hpi, when animals developed symptomatic disease,
were also used to confirm meningitis and quantify bacterial titer
by means of serial dilution and plating on CSBA culture plates.
Antibiotic treatment with ceftriaxone (100 mg/kg, i.p.
Rocephine, Roche) was initiated 18 hpi, given twice a day for up
to 5 days in long term experiments.
To assess therapeutic effect of HspB5 in pneumococcal
meningitis, animals were randomized for treatment with HspB5
or control. Recombinant human HspB5 was diluted in sterile
saline and rats were injected intracisternally (i.c.) with 10 µg
HspB5 in 10 µl saline or intraperitoneally (i.p.) with 50 µg
HspB5 in 250 µl saline. These doses were chosen based on
literature where they have been shown to be effective in a model
of experimental stroke [50 µg i.p. daily for up to 1 week (25)],
experimental autoimmune encephalomyelitis and spinal cord
injury when delivered intravenously [10 µg i.v. every other day
for 3 weeks; (21, 25, 36)]. For i.c. injections, HspB5 therapy was
initiated shortly prior to infection (2 h before) to avoid excessive
intracranial pressure by delivering inappropriate volumes of
recombinant protein and bacteria concomitantly, followed by
consecutive applications. This was done after CSF extraction
at 18 hpi, and subsequently 3 days post infection (dpi) and 5
dpi. Control animals were injected with an equal volume of
BSA in saline (10 µl of 1 mg/ml). For i.p. administration two
different protocols were tested with animals receiving HspB5 or
saline immediately prior to infection (2 h before), followed by
consecutive applications at 18 hpi, 3 dpi and 5 dpi, or receiving
HspB5 at 18 hpi, 3 dpi and 5 dpi. The examiner was blinded
regarding treatment groups for the entire experiment as well as
during data analyses.
Animals were sacrificed at two different time points for
histological analyses. Namely at 42 hpi, to investigate the
inflammatory response in the cochlea during the acute phase
after infection or 4 weeks post infection, to assess hair cell
and spiral ganglion survival. Animals were sacrificed with an
overdose of pentobarbital (15 mg/100 g), and perfused via the
left ventricle with 4 % paraformaldehyde (PFA) in phosphate-
buffered saline (PBS).
Quantitative Analysis of Cytokine
Expression on the CSF/Cytokine Analysis
in CSF
A panel of PM-associated cytokines (TNF-α, IL-6, IL-1β, IFN-
γ, and IL-10) was measured in the CSF at 18, 24 and 42 hpi
by using a magnetic multiplex assay (Rat Magnetic Luminex R©
Assay, Rat Premixed Multi-Analyte Kit, R&D Systems, Bio-
Techne) on a Bio-Plex 200 station (Bio-Rad Laboratories) as
previously described (8, 37). Five microliters CSF were diluted
to a final volume of 50 µl and at least 50 beads per analyte
were measured. Calibration curves from recombinant standards
were calculated with Bio-Plex Man-ager software (version 4.1.1)
using a five-parameter logistic curve fitting. For samples below
the detection limit, the value of detection limit provided by the
manufacturer (TNF-α, 22.1 pg/ml; IL-6, 56.0 pg/ml; IL-1β, 26.7
pg/ml; IL-10, 18.6 pg/ml; IFN-γ, 70.5 pg/ml) was multiplied by
the dilution factor.
Determination of Hearing Capacity by
Auditory Brainstem Response
Hearing capacity was assessed by recording auditory brainstem
responses (ABRs) to click and pure tone stimuli on both ears
with the Smart EP system (Intelligent Hearing Systems, Miami,
USA), as previously described (8, 34). Animals were anesthetized
with isoflurane (5 % induction, 2 % maintenance) using the
Combi-Vet Vaporizer System equipped with a digital flowmeter
(Rothacher Medical, Switzerland). One hundred-microsecond
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click stimuli and 5-ms pure tone pips (Blackman envelope;
polarity alternating) were presented at a rate of 21.1 s−1,
ranging from 100 to 20 dB SPL in 10 dB decrements (5 dB
decrements close to threshold). Responses were measured at
4, 8, 16 and 32 kHz. A total of 1,024 responses were averaged
at each sound level and filtered between 100 and 1,500Hz.
The hearing threshold was defined as the lowest intensity that
induced the appearance of a visually detectable first peak in the
recording. Later peaks were not taken in consideration for the
evaluation of the threshold as they were not reliable, especially in
infected animals.
Histological Analyses
Cryosections
Cochleae were dissected immediately after perfusion of animals
and placed for 4 h in 4 % PFA at 4◦C and subsequently decalcified
with Osteosoft (Merck, Germany) for at least 10 days.
Cochleae were dehydrated stepwise with 15 % for 2 h and 30
% sucrose overnight. Samples were embedded in optimal cutting
temperature medium (O.C.T., Sakura, Netherlands) and cut
with a cryostat (Leica CM3050 S) in 16µm thick mid-modiolar
sections, where every second section was mounted on Superfrost
Plus microscopy slides (Thermo Fisher Scientific, USA) for
quantification studies. To stain the samples, slides were put in
a Shandon Sequenza staining rack (Thermo Fisher Scientific,
USA). Sections were permeabilized for 10min with 0.1 % Triton
X-100 and blocked with blocking solution (2 % BSA, 0.01 %
Triton X-100 in PBS) for 1 h at room temperature. Samples
were incubated with primary antibodies (Table 1) overnight at
4◦C. The next day slides were rinsed and incubated with the
corresponding secondary antibody (Table 1) for 2 h at room
temperature, rinsed again and mounted with a coverslip using
Fluoroshield containing DAPI (Sigma).
Slides were visualized with a Nikon Eclipse Ti-E using a
Nikon-PLAN Fluor 4x/0.13 NA, 10x/0.3 NA, 20x/0.50 NA or
40x/1.00 NA Oil objective and by a Zeiss 710 laser scanning
microscope using a Zeiss Plan-Apochromat and 40x/1.3 NA oil
objective for hair cell quantification.
SYTO9 Staining
SYTO9 (3.34mM) and Propidium iodide (20mM) of the
LIVE/DEADBactLight Bacterial Viability Kit (Molecular Probes)
were mixed 1:1 and directly put on cochlear cryosections and
incubated for 15min at room temperature protected from
light. Sections were washed once with PBS and mounted with
Fluoroshied containing DAPI (Sigma) and visualized with a
Nikon Eclipse Ti-E using a Nikon-PLAN Fluor 40x/1.00 NA
Oil objective.
Sirius Red Staining
Cryosections of cochleae at 1 month post infection were
immersed in xylene for 10min at room temperature and
transferred to ethanol (100, 100, 80, and 70%, all 10 s) before
stained by using 0.1 % solution of Picro Sirius Red solution
(Sigma) for 1 h at room temperature. Subsequently, sections were
rinsed in 0.01N HCl for 2min. Sections were dehydrated in
ascending concentrations of ethanol (70, 80, 100, and 100%, each
TABLE 1 | Antibodies used in the study.
Species Dilution Company
PRIMARY ANTIBODY
Anti-B-iII Tublin (TUJ) Mouse 1:500 R & D Systems
Anti-Sox2 Mouse 1:200 RD Bioscience, USA
Anti-Sox10 Mouse 1:200 Santa Cruz Biotechnology,USA
Anti-myeloperoxidase (MPO) Mouse 1:500 abcam
Anti-CD68 Mouse 1:500 Serotec
Anti-CD11b/OX42 Mouse 1:500 BD Bioscience, USA
Anti-Pou4f3/Brn-3c Mouse 1:500 Santa Cruz Biotechnology,USA
Anti-alpha B-crystalline Rabbit 1:500 Abcam, UK
Anti-iba1 Rabbit 1:500 Wako
Anti-CD206 Rabbit 1:500 Abcam, UK
Anti-Cleaved Caspase 3 Rabbit 1:500 Cell Signaling
Anti-Myo7a Rabbit 1:500 Enzo Life Science
Anti-neutrophil elastase (M-18) goat 1:500 Santa Cruz Biotechnology,USA
SECONDARY ANTIBODY
Anti-goat AF488 Donkey 1:500 Molecular Probes
Anti-mouse Cy3 Donkey 1:500 Jackson (Milan, AG)
Anti-mouse Cy5 Goat 1:500 Jackson (Milan, AG)
Anti-mouse AF555 Goat 1:500 Invitrogen, USA
Anti-rabbit AF 647 Goat 1:500 Invitrogen, USA
10 s) and cleared in two stages in xylene, 10min each. Sections
were mounted with Eukitt quick-hardening mounting medium
(Fluka Analytical).
TUNEL
TUNEL assay was performed by automated staining using
Bond RX (Leica Biosystems) immunostainer. Paraffin slides were
dewaxed in Bond dewax solution (product code AR9222, Leica
Biosystems). Antigen retrieval was performed with Protease
incubation for 25min at 37◦C. TdT enzyme incubation was
performed for 20min with antibody diluent (Leica AR9352),
TdT Buffer (Promega M1893), DIG-11-dUTP (Roche, Ref
11570013910) and TdT Enzyme (Promega M1875) followed
by incubation with mouse anti DIG-FITC (1:500) for 15min
and Rabbit anti FITC (1:1000) for 15min. The reaction was
visualized using AP (Alkaline phosphatase)-rabbit polymer for
15min and fast red as red chromogen (Red polymer refine
Detection, Leica Biosystems, Ref DS9390). Finally, the samples
were counterstained with Haematoxylin and mounted with
Aquatex (Merck). Stainings were performed by the translational
research unit of the institute of Pathology, University of Bern.
Preparation of Organ of Corti Whole Mounts of Adult
Rats and Immunofluorescent Staining
The fixed and decalcified cochleae were dissected with forceps
(World Precision Instruments) and sapphire blades (World
Precision Instruments) using a Nikon SMZ800 binocular
microscope. The cochlea was cut in half, longitudinal from
the apex to the oval window through the modiolus, the apical
turn was left as one piece. Basal, middle and apical turns were
separated and hook was cut off the lowest part of the basal turn
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resulting in a total of five pieces per cochlea. The organ of Corti
was isolated by removing the lateral wall and spiral ganglion.
The tissue pieces were permeabilized with 3 % Triton X-
100 for 30min, rinsed three times with PBS, and incubated
in blocking solution for 2 h at room temperature. The hair
cell-specific antibody against Myosin7a was incubated for at
least 12 h at 4◦C. The tissue was rinsed three times with PBS
and incubated with the secondary antibodies and Phalloidin
ATTO488 (Sigma) diluted 1:500 in blocking solution overnight
at 4◦C. Each tissue piece was rinsed with PBS and incubated
for 15min with 1:1000 DAPI at room temperature before being
rinsed again and transfer to a 24 well glass bottom plate (Corning,
USA) for confocal imaging.
Image acquisition was performed with a Zeiss 710 laser
scanningmicroscope using a Zeiss Plan-Apochromat 10x/ 0.3 NA
and 20x/0.8 NA objective for hair cell quantification.
Preparation of Organ of Corti Organotypic
Cultures and Exposure to S. pneumoniae
Cochlear explants were isolated as previously reported (38).
The organ of Corti from postnatal day 2 (p2) Wistar rats
was plated on a Transwell insert (6-well format, Corning,
USA) with a permeable polyester membrane (0.4µm pore size).
Membranes were pre-coated with Cell-Tak (Corning, USA)
according to manufacturer’s protocol. Explants were cultured on
1.5ml DMEM/F12 (10 % FBS, 0.01 % Ampicillin) that was added
to the lower compartment under the insert overnight at 37 ◦C
with 5 % CO2 before any treatment.
To mimic the in vivo conditions, S. pneumoniae were added
to the medium in the lower compartment. The inoculum
concentration was chosen according to the expected bacterial
titers after bacterial proliferation in the CSF in vivo during the
acute phase (18 hpi) of PM, i.e., 1.7 × 108 cfu/ml. Bacteria
were prepared as described above and finally re-suspended
in ampicillin- and FBS-free otic medium. Organ of Corti
were exposed to bacteria for 2 h, washed and cultured for 4
more days in full otic medium (39). To assess the effect of
HspB5, recombinant human HspB5 (50µg/ml) was added to the
cultures during exposure to bacteria and the following 4 days of
cell culture.
Immunofluorescent Staining of Explants
At the end of the experiment explants were fixed with 4 % PFA
for 10min, washed and stored in PBS at 4◦C until staining.
The insert membrane was cut and explants were transferred to
a 24 well plate. Explants were permeabilized for 30min with
3 % Triton X-100 (Sigma-Aldrich, USA) and blocked for 1 h
with blocking buffer (2 % BSA, 0.01 % Triton X-100 in PBS)
at room temperature. Explants were incubated with the hair
cell specific anti-Pou4f3 antibody, the supp-orting cell marker
anti-Sox2 antibody and HspB5 specific antibody in blocking
buffer overnight at 4◦C. On the following day, tissue was rinsed
three times and incubated with the secondary antibodies at
room temperature for 2 h. Finally, samples were rinsed again
three times with PBS and mounted on a glass slide with
Fluoroshield containing DAPI (Sigma, USA). Image acquisition
was performed with a Zeiss 710 laser scanning microscope using
a Zeiss Plan-Apochromat and 20x/0.8 NA objective for hair
cell quantification.
Data Analysis of Histological Samples
Image processing was performed with the open source image
processing software FIJI, version 2.0.
Neutrophil extracellular traps (NETs) quantification: Five non-
consecutive mid-modiolar cryosections per cochlea were used
to quantify the area of the NETs (stained by MPO) in the scala
tympani. The occluded area byNET formation wasmeasured and
calculated as percentage of the area of scala tympani.
Spiral ganglion neuron quantification: The density of spiral
ganglion neurons was calculated on five non-consecutive mid-
modiolar sections by counting βIII-Tubulin positive cells
normalized to the area of the Rosenthal’s canal.
Hair cell quantification: Pou4f3 or Myo7a positive cells of the
organ of Corti were counted at three random microscopic fields
for each cochlear region (basal, middle, apical) covering in total
at least 1,200µm. The number of hair cells (IHCs andOHCs) was
expressed as unit per 100 µm.
Statistical Analysis
Statistical analysis was performed with GraphPad Prism software
(Prism 7 for Windows; GraphPad Software Inc., San Diego, CA).
Normal distribution of the datasets was tested by D’Agostino &
Pearson and KS normality test. One-way ANOVA with Tukey’s
multiple comparison test was used to evaluate whether the means
of more than two populations differ. Two-way ANOVA was
used to determine the interaction of two independent variables
(e.g., location in cochlea and treatment) on a dependent variable
(e.g., hair cell count). Unpaired t-tests were used to compare
parametric data sets of two groups. Welch’s correction was
applied if variances were not equal (F test).
If not stated otherwise, results are presented as mean values±
standard deviations. In box-plots, the horizontal line within the
box represents the median, the cross indicates the mean, the top
and the bottom of the boxmark the 75th and 25th percentiles; the
whiskers represent the range of the data (min-max). A two-tailed
p< 0.05 was considered statistically significant, with p< 0.05 (∗),
p < 0.01 (∗∗), p < 0.001 (∗∗∗) and p < 0.0001 (∗∗∗∗).
RESULTS
Pneumococcal Meningitis Induces
Inflammatory Cell Infiltration to
the Cochlea
We initially assessed the inflammatory response within the
cochlea as a consequence of bacterial meningitis. We analyzed
the presence of macrophages and neutrophils 42 h post infection,
in the acute phase of the disease, using immunostaining of
mid-modiolar sections.
In uninfected conditions, resident macrophages were present
in various locations of the cochlea. CD68+ macrophages
were most prominently found in the modiolus and the spiral
ganglion (Figure 1A; Figures S1A–C). CD206+ macrophages
were additionally seen in the spiral ligament (Figures S1G–L).
Iba1+ macrophages were numerously present in the modiolus,
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FIGURE 1 | Inflammatory infiltration of the perilymphatic spaces. Immunostainings for macrophages markers CD68 and iba1 on mid-modiolar sections of rat cochlea
(A) uninfected and (B) 42 h post infection with S. pneumonia. (C) Close up of a middle turn and (D) of the perilymphatic space. (E) Nissl staining of a cochlear middle
turn of an (E) uninfected animal and (F) 42 h post infection. (G) Higher magnification of cells infiltrating in the perilymphatic space showing the characteristic
(Continued)
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FIGURE 1 | segmented nuclei morphology of neutrophils. (H) Presence of phagocytized S. pneumoniae stained with SYTO9 (white arrows) in infiltrating leukocytes.
(I) Overview of mid-modiolar cryosections 42 h post infection stained for myeloperoxidase (MPO) and neutrophil elastase (NE) and cleaved Caspase-3 (Casp-3).
Merge and single channels are shown (J) close-up view of the perilymphatic spaces (scala vestibuli) with reticular formed neutrophil extracellular traps (NETs).
(K) TUNEL staining of a cochlear middle turn, 42 h post infection. (L) close-up of scala vestibuli. Black arrows indicate positive cells, gray arrows, extracellular DNA.
(M) Collagen staining of an uninfected animal and (N) an animal 1 month post infection. Fibrosis, detected by sirius staining, is indicated by the dashed line. Arrows
highlight loss of the organ of Corti structures and of the spiral ganglion neurons. Scale bars in overview images and middle turns indicate 200µm while scale bars of
(D,G,H,J,L) magnified perilymphatic spaces represent 20µm.
the spiral ganglion, in the spiral ligament and in stria vascularis
(Figure 1A; Figures S1A-C).
During the acute phase of the infection, macrophages
infiltrated the perilymphatic spaces in the cochlea adopting
round morphology (Figures 1B–D). Co-expression of Iba1 with
CD68 and expression of CD11b (Figures S1 D-F, M-O), were
indicative of cell activation.
Moreover, we observed infiltration of numerous granulocytes
in the perilymphatic spaces (Figures 1E–J). Nissl staining showed
that many of the infiltrating cells displayed segmented nuclei,
typical of neutrophils (Figures 1F,G). 42 h post infection SYTO9
staining revealed the presence of phagocytized S. pneumoniae
within the infiltrating leukocytes (Figure 1H).
Myeloperoxidase and neutrophil elastase staining confirmed
presence of neutrophils releasing reticular-shaped neutrophil
extracellular traps (NETs) (40) (Figures 1I,J). Concomitantly,
we observed apoptotic cell death of the infiltrating cells,
detected by cleaved caspase 3 (Figures 1I,J) and TUNEL staining
(Figures 1K,L). The latter also revealed extracellular DNA in the
perilymphatic spaces, possibly being NET-DNA (41, 42).
When cochlear histology was performed 4 weeks
post infection, in 21 % of the cases (4/19), infiltrating
granulocytes were replaced by fibrotic occlusions in the
scalae vestibuli and tympani (Figure 1N, dashed line)
ranging from slight occlusion to almost complete occlusion
of the perilymphatic space (sc. vestibuli: 18.3 to 100
%, sc. tympani: 5.6 to 72.9 %). A representative image
of fibrotic occlusion of the scala vestibuli is shown in
Figure 1N next to an uninfected animal with clear cochlear
ducts in Figure 1M. In severe cases the organ of Corti
was degenerated and spiral ganglion neurons were lost
(Figure 1N, arrows).
No inflammatory cells and no occlusions were found the
endolymphatic space.
Local Administration of HspB5 to the CSF
Space Showed Anti-inflammatory Effects
HspB5 is endogenously expressed in different cell types,
including oligodendrocytes of the CNS (21, 23) and lack of this
protein results in higher susceptibility to inflammatory damage
(21, 25). We first analyzed the endogenous localization of HspB5
in the cochlea of uninfected rats. At 12 days of age, a clear
expression of HspB5 was observed in a subset of Sox2+/Sox10+
Schwann cells in the Rosenthals’ canal (Figure 2A) surrounding
the TUJ+ spiral ganglion neurons, and also in some sparse
cells in spiral ligament and Reissner’s membrane (data not
shown). In contrast, we could not detect HspB5 within the
sensory epithelium, neither in 12 days old nor at 6 weeks of
age (data not shown), while some supporting cells in the organ
of Corti displayed positivity in very young postnatal animals at
p2 (Figure 2B).
We then tested the effects of HspB5 administration
on the inflammatory process caused by pneumococcal
meningitis. In order to obtain high local concentrations
of HspB5 in the CSF and perilymphatic spaces during the
acute phase of inflammation, the recombinant protein was
delivered directly to the cisterna magna immediately prior
to the infection and subsequently at 18 h post infection
(Figure 3A). The control group received an equivalent
amount of bovine serum albumin (BSA). Intracisternal
infection was performed by injection of 10 µl saline
containing 8.20 ± 1.8 × 105 cfu/ml living S. pneumoniae.
This concentration of the inoculum was previously shown
to cause moderate-to-severe damage to hair cells and spiral
ganglion neurons (8).
The infection resulted in similar CSF bacterial concentration
in the control (8.98 ± 6.38 × 107 cfu/ml, n = 10 animals) and
the HspB5-treated group (8.16 ± 5.88 × 107 cfu/ml, n = 8)
18 h post infection (Figure 3B). Infected animals showed reduced
weight gain (Figure 3C) and worsening of the clinical score
compared to mock-infected animals (p < 0.0001) (Figure 3D).
No significant difference in bacterial titer, weight change and
clinical score was seen between the two treatment groups (BSA
vs. HspB5). After repeated treatment with ceftriaxone, animals
recovered from the infection. Clinical conditions improved and
weight gain was normalized.
The CSF, collected at different time points after infection
(18 hpi, 24 hpi, and 42 hpi), was analyzed for inflammatory
cytokine secretion. Bacterial infection induced a rapid increase
in cytokine production. HspB5-treated animals had significantly
reduced levels of TNF-α (p < 0.05), IL-6 (p < 0.05), IL-10 (p
< 0.01), and IFN-γ (p < 0.05) at the peak of the inflammatory
process (24 hpi, Figure 3E).
When we assessed the presence of NETs at 42 hpi, we observed
up to 90 % of the area of scala tympani occluded by NETs
(Figure 3F) but we could not detect any differences as a result
of HspB5 treatment (Figure 3G).
Intracisternal Administration of HspB5
Reduced Hearing Loss
Hearing tests were performed at 1 and 4 weeks post infection
by assessing auditory brainstem responses (ABR) (Figure 4A).
Representative click-ABR recordings are shown in Figure 4B.
Rats were presented to a broadband click stimulus and pure
tones at 4, 8, 16, and 32 kHz. Hearing thresholds for clicks were
significantly elevated at 1 week post infection and persisted until
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FIGURE 2 | Endogenous expression of HspB5. (A) Immunostaining of mid-modiolar cryosection stained for HspB5 (white) and the Schwann cells markers Sox2+
(red) and Sox10+ (orange) or the neuronal marker βIII Tubulin (magenta) in p12 rats. (B) Immunostaining of organ of Corti whole mounts of p2 animals for HspB5
(white) and the supporting cells marker Sox2 (red). Scale bars in overview images indicate 200µm while scale bars of magnified areas represent 20µm.
4 weeks post infection compared to the mock-infected controls
(p < 0.0001) (Figure 4C).
Intracisternal HspB5-therapy significantly improved hearing
thresholds. We saw a trend for improved hearing thresholds of
broad band clicks compared to the untreated group already 1
week post infection (61.25 dB ± 18.63 vs. 73.5 dB ± 20.2, p =
0.053, unpaired t-test between the two infected groups, n = 10
animals per group; p = 0.0978 one-way ANOVA with Tukey’s
multiple comparison test, when including the control group.) and
the difference was statistically significant at 4 weeks post infection
(61.25 dB ± 61.25 vs. 76.5 dB ± 21.95, p = 0.0230, unpaired t-
test, n = 10 animals per group; p = 0.0406, one-way ANOVA
with Tukey’s multiple comparison test) (Figure 4C). Pure tones
ABR thresholds were lower at all frequencies tested in the HspB5-
treated group, showing statistically significant differences at 1
week post infection (two-way ANOVA, p= 0.0409) (Figure 4D),
while did not reach statistical significance at 4 weeks (Figure 4E).
Local HspB5 Delivery Protects Against
Meningitis-Induced Sensory Cell Loss
Hair cell quantification was then performed on whole mount
preparation of the organ of Corti at 4 weeks after infection
(Figure 5A). We observed a moderate inner hair cell (IHC) loss,
which was most pronounced in the hook, but no differences
between the treatment groups were observed (Figure 5B). Outer
hair cells (OHC) were instead strongly affected, especially in the
basal and mid-basal part of the organ of Corti (p<0.05, t-test).
A higher number of outer hair cells was still intact 4 weeks
after infection in the HspB5-treated group (two-way ANOVA,
p = 0.0015). Interestingly, we observed statistically significant
differences in the basal and mid-basal portions (Figure 5C).
To further confirm the protective effect of HspB5 on
the survival of hair cells to pathogen-induced damage, we
performed in vitro experiments using organotypic cultures of
the organ of Corti. Exposure of the organ of Corti explants
to bacteria for 2 h caused OHC loss, more pronounced toward
the base (Figures 5D,F). No significant changes were observed
for IHC (Figure 5E). Outer hair cells were significantly lost
at the base and middle turns compared to the unexposed
samples (base: 12.94 OHC ± 10.83 vs. 37.31 OHC ± 5.23,
middle: 24.08 OHC ± 7.95 vs. 38.39 OHC ± 3.375, p<0.05).
When HspB5 (50µg/ml) was added to the culture medium
during exposure to the bacteria and for the following 4
days, OHCs loss in the base and middle portion was no
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FIGURE 3 | Intracisternal administration of HspB5 and effects during the acute phase of pneumococcal meningitis. (A) Schematic representation of the experimental
setup to study the acute phase outcomes. Intracisternal delivery of HspB5 (red syringe) is performed immediately prior to the infection and at 18hpi. Antibiotic
treatment is initiated at 18 hpi and administered i.p. The acute phase (0–42 h) is indicated in blue. (B) Bacterial titer at 18 hpi indicates colony forming units in 1ml of
CSF (C) Relative weight change during acute infection showed a slight increase within the first 18 hpi and weight loss with the onset of clinical symptoms and
antibiotic treatment. (D) Clinical scores deteriorated during the first 24 h after infection before sick animals recovered. (E) Quantification of inflammatory cytokines in
the CSF at 18hpi, 24hpi, and 42hpi of untreated (gray, n = 9 animal) and treated animals (black, n = 10 animals) Statistical differences were assessed using unpaired
t-test with Welch correction *p < 0.05; **p < 0.01. (F) Representative immunofluorescence of NET occlusion (basal turn) in infected animals with delineated areas of
the scala tympani (white line) and NET occlusion (blue dashed line). Scale bar = 200µm. (G) The ratio between the NET-occupied area and the area of scala tympani
42 h post infection, is plotted for untreated (gray, n = 7 animals) and HspB5-treated (black, n = 4 animals).
longer statistically significantly different from the untreated
explants (Figure 5F).
Given the previously reported neuroprotective effect of
HspB5 as well as its endogenous localization in the Rosenthals’
canal, we also analyzed the survival of spiral ganglion neurons
(Figures 5G,H). We focused specifically in the basal portion of
the cochlea as we had previously reported a more significant
damage (8). The large majority of animals tested in these
experiments showed however only minimal loss of spiral
ganglion neurons after meningitis in this region (Figure 5I),
whereas middle and apical region appeared undamaged. This
did not allow to assess the putative protective effects of
HspB5 effectively.
Systemic Administration of HspB5 Had No
Effect on Pro-inflammatory Cytokine
Profile, Hair Cell Survival, and Hearing
Threshold
We additionally assessed whether HspB5 exerted effects when
administered systemically. Animals received either saline or
HspB5 intraperitoneally. Moreover, we used a paradigm more
close to clinical practice, where adjuvant treatment is initiated
concomitant to antibiotic therapy starting 18 hpi, when first
clinical signs appeared. Further HspB5 i.p. doses were applied
at day 3 and 5, as previously described in Figure 4A. Animals
were sacrificed either during the acute phase of the disease
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FIGURE 4 | Intracisternal administration of HspB5 results in improved hearing thresholds. (A) Schematic representation of the experimental setup to study late phase
outcomes. Intracisternal delivery of HspB5 (red syringe) is performed immediately prior to the infection and at 18hpi, 3 days, and 5 days post infection.
(B) Representative example of hearing thresholds of a control animal (PM-: 30 dB, left) and an infected animal (PM+: 90 dB, right). (C) ABR recording using broad
band click stimuli 1 and 4 weeks post infection in uninfected (n = 6 ears of 3 animals) and infected animals [untreated: (n = 20 ears/10 animals) and HspB5 treated: (n
= 20 ears/10 animals)]. (D) Pure tone ABR thresholds 1 and (E) 4 week post infection for untreated and HspB5 treated animals (n = 20 ears/10animals per group).
Box and whisker plot quartiles from min-max. Statistical differences were assessed by one-way ANOVA with Tukey’s multiple comparison test. #p value for unpaired
t-tests p = 0.053 (in C) and two-way ANOVA (in D,E). *p < 0.05; **p < 0.01 ****p < 0.0001.
(42 hpi), or 1 month after infection, after assessment of
hearing thresholds.
In this paradigm, we did not see a difference between the
treated and untreated animals, when animals were injected i.p.,
neither in pro-inflammatory cytokine secretion (Figure 6A), nor
for hearing thresholds (Figures 6B,C). NET formation, spiral
ganglion neuron density, hair cell number and presynaptic
ribbons counts were also not significantly influenced by the
treatment at 1 month after infection (data not shown).
We reasoned HspB5 may have reached the CSF and cochlear
fluid too late compared to the inflammatory mediators using
this treatment protocol, explaining its inefficacy. Therefore,
we assessed HspB5- i.p. treatment in an additional cohort of
animals, where administration started immediately prior to
bacterial infection, and further delivered at 18 hpi, 3 dpi, and
5 dpi, as done for the i.c. administration. Also in this case
however, we did not detect a difference in cytokine production
(Figure 6D). A trend to improved ABR hearing thresholds
was observed for broad-band clicks in the treated group at 4
weeks post infection, which however did not reach statistical
significance (Figure 6E).
These results suggest that systemic delivery may not allow
for reaching a sufficient concentration of HspB5 in the CSF and
perilymphatic space to exert a protective effect in the acute phase
of the disease.
DISCUSSION
The previously reported anti-inflammatory, anti-apoptotic and
neuroprotective effect of the small heat shock protein HspB5
(21, 30, 36, 43, 44) prompted us to examine whether HspB5
could be used as a therapeutic agent to counteract bacterial
meningitis-induced damage to the inner ear.
Our results demonstrate that intracisternal HspB5 therapy
results in an increased outer hair cell survival and improved
hearing thresholds after pneumococcal infection. This is the first
report highlighting the use of HspB5 as a potential treatment
option for bacterial meningitis-induced hearing loss.
We tested two routes of administration of the recombinant
protein: local and systemic. Delivery to the inner ear via the
round window niche was not feasible because animals suffering
from pneumococcal meningitis are in too poor health conditions
to support prolonged surgical procedures under anesthesia
during the acute phase of the disease. We therefore decided to
deliver the recombinant protein through i.c. injection, directly
into the CSF, a procedure that does not require anesthesia and
is performed very rapidly (less than a minute) in the present
model. Intracisternal injection allows for direct access to the
perilymphatic fluids, using similar routes as used by bacteria,
though the cochlear aqueduct. While i.c. delivery allows direct
access to the inner ear, the anti-inflammatory activity could also
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FIGURE 5 | HspB5 protects against S. pneumonia -induced sensory hair cell loss. (A) Representative example of a whole mount preparation of the organ of Corti
stained with hair cells specific Myo7a (green), scale bar= 50µm (B) Quantification of inner hair cells and (C) outer hair cells at 4 weeks post infection, uninfected
animals (n = 3) indicated in blue as mean (blue dashed line) and standard deviations (blue shade), hair cell count of infected animals (n = 10/group) represented in bar
graphs. 7–10 whole mount preparations were quantified per cochlea; H, hook; B, base; BM, base-middle; MA, middle-apex; A, apex. (D) Representative confocal
images of the organ of Corti immunostained for hair cells (Pou4f3, green) 4 days after exposure to S. pneumonia. Basal, middle and apical turns are shown, scale
bar= 50µm (E) quantification of inner and (F) outer hair cells in vitro without bacteria n = 4 (light blue); untreated (gray) n = 6 and HspB5-treated (black) n = 6.
(G) Mid-modiolar cross section of a control rat cochlea immunostained for the neuronal marker βIII-Tubulin (magenta) and cell nuclei (DAPI, blue), scale bar= 200µm.
(H) The Rosenthal’s canal in the basal turn is shown at higher magnification, scale bar= 20µm (I) Neuronal density quantification in the basal turn in uninfected (n =
3), infected untreated or HspB5-tretaed (n = 10 animals per group). Means with SD are indicted in the bar graphs. Dashed line with shade represents average count
of uninfected cochlea with SD. A two-way ANOVA was used for determining interaction between variables and an unpaired t-test with Welch’s correction was used for
single comparison between untreated and HspB5 treated (in B and C) *p < 0.05; **p < 0.01. A one-way ANOVA with Tukey’s multiple comparison test was used to
evaluate whether the means of the population s differ in (E,F) *p < 0.05; ***p < 0.001.
be the result of a modulation of the immune response exerted
in the meningeal spaces and in the central nervous system, for
example by binding to and modulating the activity of microglial
cells in the brain parenchyma, as shown in other models (31).
This would result consequently in less inflammatory products
reaching the inner ear. Alternatively, or in combination with
the above, local effects could be exerted through interaction
with microglia and leukocytes in the cochlea and other inner
ear compartments, or directly with cells within the sensory
epithelium. This is also supported by the experiments conducted
in vitro, where we have been able to detect hair cell protection
against S. pneumoniae-induced damage, when applying HspB5 to
the culture medium.
Local administration of HspB5 reduced inflammatory
cytokine production, namely TNF-α, IL-6, and INF-γ, which
are well-known to induce secondary inflammatory responses,
including leukocyte infiltration and scar formation (45).
It has already been reported that reduced inflammatory
cytokine production in this model of pneumococcal meningitis
is associated with reduced neuronal injury (34, 46, 47).
Furthermore, inflammatory mediators are directly implicated
in cochlear damage. For instance, TNF-α has been shown to
trigger caspase expression or activation, leading to apoptosis
(48). In vitro, excessive level of TNF-α increased the expression
of apoptosis-related genes and induced cochlear cell death
of outer hair cells in OC explant (49, 50). In vivo, anti-
inflammatory strategies using for example TNFα-antibodies
(51) or reducing the amount of TNF-α in the CSF via inhibition
of the TNF-α-converting enzyme (TACE) with doxycycline
(52), improved hearing function and reduced cochlear injury
in the context of meningitis (51). In the present study, we
detected reduced concentrations of TNF-α during bacterial
meningitis in animals treated with HspB5 and observed
attenuated hearing loss with better hair cell survival after
recovery from infection in the these animals compared to the
untreated cohort.
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FIGURE 6 | Intraperitoneal administration of HspB5 does not change inflammatory cytokine profiles nor hearing thresholds. (A) Animals received a single HspB5 i.p.
injection at 18hpi. Quantification of inflammatory cytokines in the CSF at 18, 24, and 42 h post infection; untreated (n = 9, gray) and HspB5-treated (n = 10, black) (B)
Animals received a HspB5 i.p. injections at 18hpi, 3 days, and 5 days post infection. ABR hearing thresholds for clicks and pure tones 1 week and (C) 3 weeks post
infection; untreated (n = 26 ears/13 animals, gray) and HspB5-treated (n = 26 ears/13 animals, black). (D) Animals received i.p. injections 2 h prior to infection, as well
as at 18 hpi. Quantification of inflammatory cytokines in the CSF at 18, 24, and 42 h post infection; untreated (n = 11, gray) and HspB5-treated (n = 10, black) (E)
Animals received i.p. injections 2 h prior to infection, as well as at 18 hpi, 3 days, and 5 days post infection. ABR hearing thresholds for clicks 4 weeks post infection;
(n = 28 ears/14 animals, gray) and HspB5-treated (n = 24 ears/12 animals black). Box and whisker plot quartiles from min-max. Graphs show mean values with
standard deviation. Statistical differences were assessed by single comparison using unpaired t-test and two-way ANOVA.
Interleukin-10 induction instead has been previously
observed exclusively in severely infected animals (8), suggesting
a secondary anti-inflammatory response. HspB5 dampening of
IL-10 levels may correlate with an overall reduced inflammation.
Neutrophil activity, assessed here by NET formation in the
perilymphatic space was however not sensitive to HspB5. The
role of NETs, as well as all other inflammatory processes required
for bacterial clearance and resolution of the infection, are
nevertheless dual and while implicated in the development of the
pathology, they are needed to protect against infections (53, 54).
We have also attempted to quantify the numbers of macrophages
infiltrating in the cochlea in response tomeningitis and in the two
treatment groups. We specifically focused on Iba1+ cells in the
Rosenthal’s canal. While we did not observe differences between
the HspB5 and the saline-treated groups (data not shown), the
branched morphology of the cells does not allow for a precise
assessment using tissue sections. Alternative imaging modalities
of entire cochlea whole mounts (7) would need to be optimized
in order to adequately address this question.
In PM, where the damage is induced by an acute inflammatory
reaction, limited to approximately 40 h, the time window for
action of an effective anti-inflammatory therapy is limited.
Reaching sufficiently high local concentration of the compound
in a timely adequate manner is therefore technically challenging.
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We tried to control for this aspect by delivering HspB5 therapy
at the time of infection and further applied the at 18 h post
infection. This should allow for a high local concentration at the
time point when the cytokine burst occurs. While the i.c. delivery
significantly reduced inflammatory cytokine production in this
paradigm, i.p. injection using the same schedule was ineffective.
It has been reported that HspB5 is able to cross the blood brain
barrier especially under inflammatory conditions (36, 55). Since
pneumococcal meningitis causes increased permeability of the
blood brain barrier, and the overshooting cochlear inflammation
is accompanied by blood labyrinth barrier disruption, proven
by increased Evans Blue extravasation (12, 56), we assumed
HspB5 would cross both barriers also during pneumococcal
meningitis. However, we did not observe any changes in the
inflammatory reaction, cytokine production or sensorineural
hearing loss phenotypes, when HspB5 was delivered systemically.
The results of the systemic delivery paradigm therefore bring
about the question of whether HspB5 did not reach, or did
not reach in sufficient amount, or at the right time point,
the inner ear and CSF since our effort to detect the i.p.
delivered compound by classical immunostaining of the cochleae
was unsuccessful.
In clinical practice, HspB5 could be applied directly in the CSF
space, in a timely manner. Alternatively, intratympanic injection
may be rather feasible in a human patient compared to infant rats.
Testing the compounds in different models, involving less severe
but chronic inflammation such chronic exposure to moderate
levels of noise (57), may be alternatively used to better reveal the
role of HspB5 in oto-protection.
In conclusion, our data provides evidence that HspB5, when
administrated adequately, attenuates the inflammatory response
and results in better outer hair cell survival with improved
hearing thresholds. Since HspB5 was only beneficial when given
directly to the CSF compartment at the time of infection, but not
when delayed longer and delivered systemically, the early changes
in cytokine expression observed upon HspB5 treatment may be
crucial to conferring protection.
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Figure S1 | Macrophages in the cochlea. (A–C) Mid-modialar section of
uninfected rat cochlea immunostained for CD68 (magenta) and iba1 (yellow),
(D–F) Mid-modiloar sections of rat cochlea 42 hours post infection with S.
pneumoniae immunostained for CD68 and iba1, (G–I) uninfected cochleae
stained for CD68 (magenta) and CD206 (gray), (J–L) cochleae 42 hours post
infection stained for CD68 and CD206, scale bars = 20µm. (M) Representative
example of CD11b (yellow) immunostaining and DAPI (blue) in uninfected animals
and (N) 42hpi, scale bars = 200µm (O) detail of the cells in the perilymphatic
space, scale bar = 20 µm.
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